Improvement of bone metabolism after infliximab therapy in Crohn's disease;Infliximabkezelés hatása a csontanyagcserére Crohn-betegségben

Orvosi Hetilap

Volumn 146, Issue 28, 2005, Pages 1477-1480

  Miheller, Pál ^a   Muzes, Györgyi ^a   Zágoni, Tamás ^a   Tóth, Miklós ^a   Rácz, Károly ^a   Tulassay, Zsolt ^a  

^a NONE

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Osteoporosis; Tumor necrosis factor

Indexed keywords

BIOCHEMICAL MARKER; INFLIXIMAB; OSTEOCALCIN; BIOLOGICAL MARKER; COLLAGEN; GASTROINTESTINAL AGENT; GLUTAMYL LYSYL ALANYL HISTIDYL ASPARTYL GLYCYL GLYCYL ARGININE; GLUTAMYL-LYSYL-ALANYL-HISTIDYL-ASPARTYL-GLYCYL-GLYCYL-ARGININE; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; BONE; DRUG EFFECT; METABOLISM; OSTEOPOROSIS;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; COLLAGEN; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 25444467246     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Azuma, Y., Kaji, K., Katogi, R. és mtsai: Tumor necrosis factor alpha-induces differentiation and bone resorption by osteoclasts. J. Biol. Chem., 2000, 257, 4858-4864.
2. Best, W. R., Becktel, J. M., Singleton, J. W. és mtsa: Development of a Crohn's disease activity index. National Cooperative Crohn's disease Study. Gastroenterology., 1976, 70, 439-444.
3. Dinca, M., Fries, W., Lusietto, G. és mtsai: Evolution of osteopenia in inflammatory bowel disease., Am. J. Gastroenterol., 1999, 94, 1292-1297.
4. Fernandez-Martin, J. L., Kurian, S., Farmer, P. és mtsa: Tumor necrosis factor activates a nuclear inhibition of vitamin D and retinoid-X receptors. Mol. Cell. Endocrinol., 1998, 141, 65-72.
5. Lee, S. E., Chung, W. J., Kwak, H. B. és mtsai: Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J. Biol. Chem., 2001, 276, 49343-49349.
6. Martin, J. P., Tonge, K. A., Bhonsle, U. és mtsai: Bone mineral densitiy in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 1999, 11, 537-541.
7. Pollak, R. D., Karmeli, F., Eliakim, R. és mtsai: Femoral neck osteopenia in pateints with inflammatory bowel disease. Am. J. Gastroenterol., 1988, 93, 1483-1489.
8. Szathmári, M., Prónai, L., Tulassay Z.: Altered bone metabolism in inflammatory bowel disease. Am. J. Gastroenterol., 1988, 93, 848-849.
9. Thomson, B. M., Mundy, G. R., Chambers T. J: Tumor necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J. Immunol., 1987, 138, 775-779.
10. Valentine, J. F., Sninsky, M. D.: Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am. J. Gastroenterol., 1999, 94, 878-883.